Recon: FDA approves Gilead’s twice-yearly HIV shot; Two top FDA cell and gene therapy leaders pushed out

ReconReconBiologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States